The Prognostic Value of Nanog Overexpression in Lung Cancer: A Meta-Analysis

Table 3

Subgroup analysis of OS by pathological types, publication year, NOS score, and country.

Subgroup	No. of studies	No. of patients	P value	Pooled HR (95% CI)	PHet	I^2 (%)
Pathological types
Adenocarcinoma	5	613	≤0.001	1.68 (1.34-2.11)	0.375	5.6%
Squamous cell carcinoma	2	105	0.270	1.97 (0.59-6.55)	0.009	85.4%
Small cell carcinoma	1	50	0.402	1.74 (0.70-2.23)
Publication year
2010-2016	8	1150	≤0.001	1.56 (1.33-1.83)	0.819	0.0%
2017	2	222	≤0.001	2.94 (2.22-3.88)	0.896	0.0%
NOS score
<7	4	374	0.004	1.46 (1.12-1.89)	0.432	0.0%
≥7	6	998	≤0.001	2.01 (1.55-2.60)	0.038	57.6%
Country
China	6	874	≤0.001	1.57 (1.32-1.87)	0.671	0.0%
Other	4	498	≤0.001	2.20 (1.52-3.19)	0.051	61.5%

OS, overall survival; NO, number of sample size; HR, hazard ratio; CI, confidence interval; NOS, Newcastle-Ottawa-Scale.